Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2093095rdf:typepubmed:Citationlld:pubmed
pubmed-article:2093095lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:2093095lifeskim:mentionsumls-concept:C2936522lld:lifeskim
pubmed-article:2093095lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:2093095lifeskim:mentionsumls-concept:C1515877lld:lifeskim
pubmed-article:2093095lifeskim:mentionsumls-concept:C1883712lld:lifeskim
pubmed-article:2093095lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:2093095lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:2093095lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:2093095pubmed:issue6lld:pubmed
pubmed-article:2093095pubmed:dateCreated1991-6-18lld:pubmed
pubmed-article:2093095pubmed:abstractText1. The cardiovascular effects of the 5-HT2 antagonist ICI 169,369 have been investigated in pentobarbitone anaesthetized rats and in pithed rats whose blood pressure was supported by a vasopressin infusion. 2. In anaesthetized rats, cumulative doses (0.1-3.0 mg kg-1) of ICI 169,369 caused dose-related large transient falls in heart rate and blood pressure followed by a slow dose-related decline in both parameters. 3. Pretreatment with atropine methonitrate (1 mg kg-1) alone or in combination with atenolol (1 mg kg-1) or bi-vagotomy blocked the transient changes in blood pressure and heart rate caused by ICI 169,369. The long-term fall in heart rate was also attenuated by either atropine or atenolol; however, the combination of atenolol and atropine was more effective. None of the above pretreatments affected the long-term fall in blood pressure caused by ICI 169,369. 4. The cardiovascular effects of ICI 169,369 were unaffected by pretreatment with MDL 72222 (1 mg kg-1) and failed to show cross-tachyphylaxis with phenylbiguanide. 5. In pithed rats whose blood pressure was maintained with vasopressin, ICI 169,369 failed to cause any of the above transient and long-term effects on blood pressure and heart rate. 6. The study indicates that ICI 169,369 is capable of stimulating cardiopulmonary afferents through a non 5-HT3 receptor mechanism and has a central hypotensive action.lld:pubmed
pubmed-article:2093095pubmed:languageenglld:pubmed
pubmed-article:2093095pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2093095pubmed:citationSubsetIMlld:pubmed
pubmed-article:2093095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2093095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2093095pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2093095pubmed:statusMEDLINElld:pubmed
pubmed-article:2093095pubmed:monthDeclld:pubmed
pubmed-article:2093095pubmed:issn0144-1795lld:pubmed
pubmed-article:2093095pubmed:authorpubmed-author:PiresJ GJGlld:pubmed
pubmed-article:2093095pubmed:authorpubmed-author:RamageA GAGlld:pubmed
pubmed-article:2093095pubmed:issnTypePrintlld:pubmed
pubmed-article:2093095pubmed:volume10lld:pubmed
pubmed-article:2093095pubmed:ownerNLMlld:pubmed
pubmed-article:2093095pubmed:authorsCompleteYlld:pubmed
pubmed-article:2093095pubmed:pagination345-51lld:pubmed
pubmed-article:2093095pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:meshHeadingpubmed-meshheading:2093095-...lld:pubmed
pubmed-article:2093095pubmed:year1990lld:pubmed
pubmed-article:2093095pubmed:articleTitleEvidence suggesting that the 5-HT2 antagonist ICI 169,369 activates vagal afferents and in addition has a central hypotensive action in anaesthetized rats.lld:pubmed
pubmed-article:2093095pubmed:affiliationAcademic Department of Pharmacology, Royal Free Hospital School of Medicine, Hampstead, London, UK.lld:pubmed
pubmed-article:2093095pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2093095pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed